PMC:7321036 / 77799-78600 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T2","span":{"begin":406,"end":413},"obj":"https://glytoucan.org/Structures/Glycans/G15021LG"}],"text":"Viruses (Mount Sinai, New York)\nFor infection experiments in ACE2-A549 cells, SARS-CoV-2, isolate USA-WA1/2020 (NR-52281), which shares 99.983% sequence identity with the BetaCoV/France/IDF0372/2020 isolate, was deposited by the Center for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH. SARS-CoV-2 was propagated in Vero E6 cells in DMEM supplemented with 2% FBS, 4.5 g/L D-glucose, 4 mM L-glutamine, 10 mM Non-Essential Amino Acids, 1 mM Sodium Pyruvate and 10 mM HEPES as described previously (Blanco-Melo et al., 2020). All work involving live SARS-CoV-2 was performed in the CDC/USDA-approved BSL-3 facility of the Global Health and Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai in accordance with institutional biosafety requirements."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T594","span":{"begin":71,"end":76},"obj":"Body_part"},{"id":"T595","span":{"begin":356,"end":361},"obj":"Body_part"},{"id":"T596","span":{"begin":406,"end":413},"obj":"Body_part"},{"id":"T597","span":{"begin":422,"end":431},"obj":"Body_part"},{"id":"T598","span":{"begin":453,"end":464},"obj":"Body_part"}],"attributes":[{"id":"A594","pred":"fma_id","subj":"T594","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A595","pred":"fma_id","subj":"T595","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A596","pred":"fma_id","subj":"T596","obj":"http://purl.org/sig/ont/fma/fma82743"},{"id":"A597","pred":"fma_id","subj":"T597","obj":"http://purl.org/sig/ont/fma/fma82752"},{"id":"A598","pred":"fma_id","subj":"T598","obj":"http://purl.org/sig/ont/fma/fma82739"}],"text":"Viruses (Mount Sinai, New York)\nFor infection experiments in ACE2-A549 cells, SARS-CoV-2, isolate USA-WA1/2020 (NR-52281), which shares 99.983% sequence identity with the BetaCoV/France/IDF0372/2020 isolate, was deposited by the Center for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH. SARS-CoV-2 was propagated in Vero E6 cells in DMEM supplemented with 2% FBS, 4.5 g/L D-glucose, 4 mM L-glutamine, 10 mM Non-Essential Amino Acids, 1 mM Sodium Pyruvate and 10 mM HEPES as described previously (Blanco-Melo et al., 2020). All work involving live SARS-CoV-2 was performed in the CDC/USDA-approved BSL-3 facility of the Global Health and Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai in accordance with institutional biosafety requirements."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T331","span":{"begin":36,"end":45},"obj":"Disease"},{"id":"T332","span":{"begin":78,"end":86},"obj":"Disease"},{"id":"T333","span":{"begin":319,"end":327},"obj":"Disease"},{"id":"T334","span":{"begin":579,"end":587},"obj":"Disease"}],"attributes":[{"id":"A331","pred":"mondo_id","subj":"T331","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A332","pred":"mondo_id","subj":"T332","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A333","pred":"mondo_id","subj":"T333","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A334","pred":"mondo_id","subj":"T334","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Viruses (Mount Sinai, New York)\nFor infection experiments in ACE2-A549 cells, SARS-CoV-2, isolate USA-WA1/2020 (NR-52281), which shares 99.983% sequence identity with the BetaCoV/France/IDF0372/2020 isolate, was deposited by the Center for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH. SARS-CoV-2 was propagated in Vero E6 cells in DMEM supplemented with 2% FBS, 4.5 g/L D-glucose, 4 mM L-glutamine, 10 mM Non-Essential Amino Acids, 1 mM Sodium Pyruvate and 10 mM HEPES as described previously (Blanco-Melo et al., 2020). All work involving live SARS-CoV-2 was performed in the CDC/USDA-approved BSL-3 facility of the Global Health and Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai in accordance with institutional biosafety requirements."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1089","span":{"begin":0,"end":7},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T1090","span":{"begin":66,"end":70},"obj":"http://purl.obolibrary.org/obo/CLO_0001601"},{"id":"T1091","span":{"begin":66,"end":70},"obj":"http://purl.obolibrary.org/obo/CLO_0050025"},{"id":"T1092","span":{"begin":66,"end":70},"obj":"http://purl.obolibrary.org/obo/CLO_0054264"},{"id":"T1093","span":{"begin":66,"end":70},"obj":"http://purl.obolibrary.org/obo/CLO_0054265"},{"id":"T1094","span":{"begin":66,"end":70},"obj":"http://purl.obolibrary.org/obo/CLO_0054266"},{"id":"T1095","span":{"begin":66,"end":70},"obj":"http://purl.obolibrary.org/obo/CLO_0054267"},{"id":"T1096","span":{"begin":66,"end":70},"obj":"http://purl.obolibrary.org/obo/CLO_0054268"},{"id":"T1097","span":{"begin":66,"end":70},"obj":"http://purl.obolibrary.org/obo/CLO_0054269"},{"id":"T1098","span":{"begin":71,"end":76},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T1099","span":{"begin":348,"end":361},"obj":"http://purl.obolibrary.org/obo/CLO_0051719"},{"id":"T1100","span":{"begin":611,"end":614},"obj":"http://purl.obolibrary.org/obo/CL_0000990"}],"text":"Viruses (Mount Sinai, New York)\nFor infection experiments in ACE2-A549 cells, SARS-CoV-2, isolate USA-WA1/2020 (NR-52281), which shares 99.983% sequence identity with the BetaCoV/France/IDF0372/2020 isolate, was deposited by the Center for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH. SARS-CoV-2 was propagated in Vero E6 cells in DMEM supplemented with 2% FBS, 4.5 g/L D-glucose, 4 mM L-glutamine, 10 mM Non-Essential Amino Acids, 1 mM Sodium Pyruvate and 10 mM HEPES as described previously (Blanco-Melo et al., 2020). All work involving live SARS-CoV-2 was performed in the CDC/USDA-approved BSL-3 facility of the Global Health and Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai in accordance with institutional biosafety requirements."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T56206","span":{"begin":112,"end":114},"obj":"Chemical"},{"id":"T90504","span":{"begin":404,"end":413},"obj":"Chemical"},{"id":"T18276","span":{"begin":406,"end":413},"obj":"Chemical"},{"id":"T24858","span":{"begin":420,"end":431},"obj":"Chemical"},{"id":"T63958","span":{"begin":422,"end":431},"obj":"Chemical"},{"id":"T28837","span":{"begin":497,"end":502},"obj":"Chemical"}],"attributes":[{"id":"A67132","pred":"chebi_id","subj":"T56206","obj":"http://purl.obolibrary.org/obo/CHEBI_145751"},{"id":"A46053","pred":"chebi_id","subj":"T90504","obj":"http://purl.obolibrary.org/obo/CHEBI_17634"},{"id":"A42924","pred":"chebi_id","subj":"T90504","obj":"http://purl.obolibrary.org/obo/CHEBI_4167"},{"id":"A38536","pred":"chebi_id","subj":"T90504","obj":"http://purl.obolibrary.org/obo/CHEBI_42758"},{"id":"A3364","pred":"chebi_id","subj":"T18276","obj":"http://purl.obolibrary.org/obo/CHEBI_17234"},{"id":"A2270","pred":"chebi_id","subj":"T24858","obj":"http://purl.obolibrary.org/obo/CHEBI_18050"},{"id":"A31402","pred":"chebi_id","subj":"T24858","obj":"http://purl.obolibrary.org/obo/CHEBI_30011"},{"id":"A32891","pred":"chebi_id","subj":"T24858","obj":"http://purl.obolibrary.org/obo/CHEBI_58359"},{"id":"A96690","pred":"chebi_id","subj":"T63958","obj":"http://purl.obolibrary.org/obo/CHEBI_28300"},{"id":"A37817","pred":"chebi_id","subj":"T28837","obj":"http://purl.obolibrary.org/obo/CHEBI_46756"}],"text":"Viruses (Mount Sinai, New York)\nFor infection experiments in ACE2-A549 cells, SARS-CoV-2, isolate USA-WA1/2020 (NR-52281), which shares 99.983% sequence identity with the BetaCoV/France/IDF0372/2020 isolate, was deposited by the Center for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH. SARS-CoV-2 was propagated in Vero E6 cells in DMEM supplemented with 2% FBS, 4.5 g/L D-glucose, 4 mM L-glutamine, 10 mM Non-Essential Amino Acids, 1 mM Sodium Pyruvate and 10 mM HEPES as described previously (Blanco-Melo et al., 2020). All work involving live SARS-CoV-2 was performed in the CDC/USDA-approved BSL-3 facility of the Global Health and Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai in accordance with institutional biosafety requirements."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1737","span":{"begin":61,"end":65},"obj":"Gene"},{"id":"1738","span":{"begin":78,"end":88},"obj":"Species"},{"id":"1739","span":{"begin":171,"end":178},"obj":"Species"},{"id":"1740","span":{"begin":319,"end":329},"obj":"Species"},{"id":"1741","span":{"begin":579,"end":589},"obj":"Species"},{"id":"1742","span":{"begin":365,"end":369},"obj":"Chemical"},{"id":"1743","span":{"begin":406,"end":413},"obj":"Chemical"},{"id":"1744","span":{"begin":420,"end":431},"obj":"Chemical"},{"id":"1745","span":{"begin":471,"end":486},"obj":"Chemical"},{"id":"1746","span":{"begin":497,"end":502},"obj":"Chemical"},{"id":"1747","span":{"begin":36,"end":45},"obj":"Disease"},{"id":"1748","span":{"begin":66,"end":70},"obj":"CellLine"},{"id":"1749","span":{"begin":353,"end":355},"obj":"CellLine"}],"attributes":[{"id":"A1737","pred":"tao:has_database_id","subj":"1737","obj":"Gene:59272"},{"id":"A1738","pred":"tao:has_database_id","subj":"1738","obj":"Tax:2697049"},{"id":"A1739","pred":"tao:has_database_id","subj":"1739","obj":"Tax:694002"},{"id":"A1740","pred":"tao:has_database_id","subj":"1740","obj":"Tax:2697049"},{"id":"A1741","pred":"tao:has_database_id","subj":"1741","obj":"Tax:2697049"},{"id":"A1743","pred":"tao:has_database_id","subj":"1743","obj":"MESH:D005947"},{"id":"A1744","pred":"tao:has_database_id","subj":"1744","obj":"MESH:D005973"},{"id":"A1746","pred":"tao:has_database_id","subj":"1746","obj":"MESH:D006531"},{"id":"A1747","pred":"tao:has_database_id","subj":"1747","obj":"MESH:D007239"},{"id":"A1748","pred":"tao:has_database_id","subj":"1748","obj":"CVCL:0023"},{"id":"A1749","pred":"tao:has_database_id","subj":"1749","obj":"CVCL:4582"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Viruses (Mount Sinai, New York)\nFor infection experiments in ACE2-A549 cells, SARS-CoV-2, isolate USA-WA1/2020 (NR-52281), which shares 99.983% sequence identity with the BetaCoV/France/IDF0372/2020 isolate, was deposited by the Center for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH. SARS-CoV-2 was propagated in Vero E6 cells in DMEM supplemented with 2% FBS, 4.5 g/L D-glucose, 4 mM L-glutamine, 10 mM Non-Essential Amino Acids, 1 mM Sodium Pyruvate and 10 mM HEPES as described previously (Blanco-Melo et al., 2020). All work involving live SARS-CoV-2 was performed in the CDC/USDA-approved BSL-3 facility of the Global Health and Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai in accordance with institutional biosafety requirements."}

{"project":"LitCovid-sentences","denotations":[{"id":"T711","span":{"begin":0,"end":31},"obj":"Sentence"},{"id":"T712","span":{"begin":32,"end":318},"obj":"Sentence"},{"id":"T713","span":{"begin":319,"end":554},"obj":"Sentence"},{"id":"T714","span":{"begin":555,"end":801},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Viruses (Mount Sinai, New York)\nFor infection experiments in ACE2-A549 cells, SARS-CoV-2, isolate USA-WA1/2020 (NR-52281), which shares 99.983% sequence identity with the BetaCoV/France/IDF0372/2020 isolate, was deposited by the Center for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH. SARS-CoV-2 was propagated in Vero E6 cells in DMEM supplemented with 2% FBS, 4.5 g/L D-glucose, 4 mM L-glutamine, 10 mM Non-Essential Amino Acids, 1 mM Sodium Pyruvate and 10 mM HEPES as described previously (Blanco-Melo et al., 2020). All work involving live SARS-CoV-2 was performed in the CDC/USDA-approved BSL-3 facility of the Global Health and Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai in accordance with institutional biosafety requirements."}

{"project":"2_test","denotations":[{"id":"32645325-32416070-20773109","span":{"begin":548,"end":552},"obj":"32416070"}],"text":"Viruses (Mount Sinai, New York)\nFor infection experiments in ACE2-A549 cells, SARS-CoV-2, isolate USA-WA1/2020 (NR-52281), which shares 99.983% sequence identity with the BetaCoV/France/IDF0372/2020 isolate, was deposited by the Center for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH. SARS-CoV-2 was propagated in Vero E6 cells in DMEM supplemented with 2% FBS, 4.5 g/L D-glucose, 4 mM L-glutamine, 10 mM Non-Essential Amino Acids, 1 mM Sodium Pyruvate and 10 mM HEPES as described previously (Blanco-Melo et al., 2020). All work involving live SARS-CoV-2 was performed in the CDC/USDA-approved BSL-3 facility of the Global Health and Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai in accordance with institutional biosafety requirements."}